Intrommune Therapeutics Presents Oral Mucosal Immunotherapy Updates at Leading Industry Events
21 Mayo 2024 - 8:35AM
Intrommune Therapeutics, Inc., a biotechnology company committed to
developing a patient-friendly treatment platform for people with
peanut and other food allergies, is pleased to announce its
participation in three renowned industry events during May. Last
week, the Intrommune team presented in support of its Oral Mucosal
Immunotherapy (OMIT) at Citizens JMP Life Science Conference and
the BioNJ BioPartnering Conference, and CEO Michael Nelson will
represent Intrommune as a panelist at this year’s Annual Food
Allergy Fund Summit.
On May 13th, the Intrommune Executive Team attended Citizens JMP
Life Science Conference in New York City to discuss its Phase 1
OMEGA clinical trial in adults with peanut allergies, resulting in
an enthusiastic reception from industry colleagues, fellow
executives, and investors alike. The presented data demonstrates
that OMIT, an investigational treatment which delivers allergenic
proteins via an innovative, specially formulated toothpaste, can
safely be used to treat patients with food allergies in a more
convenient way than food allergy therapies currently on the
market.
Just a day later, Intrommune presented as an Emerging Company at
the BioNJ BioPartnering Conference in Jersey City, NJ. As the
premier partnering event in New Jersey, companies selected to take
the stage on May 14th represented the most compelling new
technologies in the biotech space, and Intrommune is thrilled to
have been given the opportunity to connect with those in
attendance.
Following these presentations, Intrommune CEO Michael Nelson
will be featured in the “Key Innovations: Novel Platforms and
Technology Companies CEOs” panel at the 2024 Food Allergy Fund
Summit this week. The summit gathers many of today's brightest
minds and most influential voices in biotech, highlighting
cutting-edge developments in food allergy with a focus on advancing
allergy care as a whole. The CEO panel will be held on May 23rd at
1:00pm EDT.
About the OMEGA TrialIntrommune Therapeutic’s
Phase 1 OMEGA Clinical Study was a randomized, double-blind,
placebo-controlled study that enrolled 32 adults (ages 18-55) with
peanut allergy in a 3:1 ratio to receive either an escalating dose
of INT301 or placebo. The study groups were blinded to the
investigator, patients, and sponsor. During the course of the
trial, the United States Food and Drug Administration allowed
amendments to the OMEGA Clinical Study protocol to determine the
maximally tolerated dose and to allow the addition of a maintenance
period which included a double-blind, placebo controlled oral food
challenge at the end of the trial.
About Peanut and Other Food
AllergiesUnfortunately, food allergy remains an area of
tremendous unmet medical need, affecting more than 220 million
people worldwide, including approximately 33 million people in the
United States. Management of food allergies currently focuses on
avoidance of exposure to triggering foods, though often such foods,
including peanuts, are common ingredients in food products and
therefore difficult to avoid. Many people with peanut allergy are
accidentally exposed and experience potentially life-threatening
reactions, including anaphylaxis.
About Oral Mucosal Immunotherapy™Oral Mucosal
Immunotherapy (OMIT) utilizes complex patented biochemical
processes to stabilize and deliver allergenic proteins in a fully
functional toothpaste. By simply brushing your teeth, the
allergenic proteins are delivered to immunologically active areas
of the oral cavity with the greatest potential for allergy
desensitization. Success with allergy immunotherapy hinges on
consistent exposure of a patient’s immune system to gradually
“desensitize” the patient to the specific allergy trigger over
time. OMIT presents advantages over other approaches to allergy
immunotherapy due to its targeted delivery and simplified
administration, supporting improved adherence.
About Intrommune TherapeuticsIntrommune,
dedicated to improving and protecting the lives of people with food
allergy, is developing the revolutionary oral mucosal immunotherapy
(OMIT) treatment platform for food allergies. OMIT is a
patient-friendly solution for over 220 million people worldwide,
including 33 million people in the United States, who suffer from
life-altering food allergies. Intrommune Therapeutic’s lead
product, INT301, has completed its Phase 1 clinical trial. All
Phase 1 results along with future studies are intended to support
OMIT as being a safe, effective and convenient therapy for patients
who suffer from peanut and other food allergies.
For more information on Intrommune Therapeutics, please visit
www.intrommune.com
Contact:Stuart LoeschIntrommune
Therapeutics(484) 942-0323sloesch@intrommune.com
Cautionary Statement Regarding Forward-Looking Statements
This release may contain “forward-looking statements.”
Forward-looking statements are identified by certain words or
phrases such as “may,” “will,” “aim,” “will likely result,”
“believe,” “expect,” “will continue,” “anticipate,” “estimate,”
“intend,” “plan,” “contemplate,” “seek to,” “future,” “objective,”
“goal,” “project,” “should,” “will pursue” and similar expressions
or variations of such expressions. These forward-looking statements
reflect the company’s current expectations about its future plans
and performance. These forward-looking statements rely on a number
of assumptions and estimates which could be inaccurate and which
are subject to risks and uncertainties. Actual results could vary
materially from those anticipated or expressed in any
forward-looking statement made by the company. The company
disclaims any obligation or intent to update the forward-looking
statements in order to reflect events or circumstances after the
date of this release.
This release does not contain or constitute an offer to sell or
a solicitation of any offer to buy securities in the United States
or in any other jurisdiction.